Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LCK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LCK Active Kinase Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic assays. |
View LCK Products |
| Gene Delivery | LCK Promise-ORF / Lentivirus Full-length ORF for stable cell lines in Jurkat or primary T-cells. |
View LCK Products |
| Benchmark Ab | Anti-LCK Recombinant Antibody High-affinity clone for Western Blot, IHC, and Flow Cytometry validation. |
View LCK Products |
| Validator | LCK siRNA Set For target knockdown and specificity verification in cell-based assays. |
View LCK Products |
| Related Target A | ZAP70 Immediate downstream kinase in TCR signaling; essential for cascade validation. |
View ZAP70 Products |
| Related Target B | FYN Src-family kinase homolog; critical counter-screening target for selectivity. |
View FYN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog Selectivity (Src-family cross-reactivity) | Recombinant active FYN, SRC, and LYN proteins available with sequence verification for counter-screening. |
| Drug Resistance Profiling | Gatekeeper mutant (e.g., T316M) kinase domains custom-designed with theoretical MW verification. |
| Lack of Controls | Recombinant detection antibodies and sequence-verified positive controls included. |
| False Positives in Screening | High-knockdown efficiency siRNA sets included for target validation. |
Live LCK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LCK therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective small molecules and allosteric modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting autoimmune diseases (such as Rheumatoid Arthritis and Lupus) and T-cell malignancies, while emerging studies explore LCK modulation to prevent CAR-T cell exhaustion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | Bristol Myers Squibb, Pfizer | Autoimmune Diseases, Transplant Rejection | Kinase Selectivity Assay (Need high-purity active LCK and homolog panel) |
| Allosteric Inhibitors | Academic Institutions, Biotech Startups | T-Cell Acute Lymphoblastic Leukemia (T-ALL) | Conformational Stability (Need sequence-verified full-length or domain-specific proteins) |
| CAR-T Modulators | Oncology Biotechs | Solid Tumors (CAR-T exhaustion) | Cell Line Construction (Need Lentivirus for stable expression in T-cells) |